| 08/12/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/12/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEFA14A | |
| 08/11/2026 7:45 AM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 08/11/2026 7:49 AM | Conduit Pharmaceuticals (1896212) Filer | Form ARS | |
| 07/31/2026 4:26 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 07/16/2026 7:05 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/15/2026 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/07/2026 4:20 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/29/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2026 5:40 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for CDTTW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/23/2026 5:42 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D/A | |
| 06/16/2026 4:00 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 7:51 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 05/20/2026 6:03 PM | Conduit Pharmaceuticals (1896212) Subject Nirland Ltd (1994188) Filed by | Form SCHEDULE 13G | |
| 05/14/2026 7:42 AM | Conduit Pharmaceuticals (1896212) Issuer Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 7:47 AM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 05/03/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 05/01/2026 4:11 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 04/30/2026 7:16 PM | Conduit Pharmaceuticals (1896212) Issuer Olsen Ulrik K (2132215) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/21/2026 8:56 PM | Conduit Pharmaceuticals (1896212) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 04/15/2026 4:01 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/30/2026 8:21 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D | |
| 03/30/2026 8:22 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/30/2026 8:23 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/25/2026 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/18/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/06/2026 3:12 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 02/24/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 02/23/2026 7:27 PM | Conduit Pharmaceuticals (1896212) Issuer Farley Chele Chiavacci (1908750) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 5:26 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 02/09/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 01/30/2026 8:06 AM | Conduit Pharmaceuticals (1896212) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 01/22/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/02/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Issuer Corvus Capital Ltd. (1990829) Reporting Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2025 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/09/2025 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/22/2025 4:56 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad) In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night.
Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. See Jim Rickards' full market warning and what it means for your portfolio |
| 09/19/2025 3:46 PM | Bligh James (1990748) Reporting Conduit Pharmaceuticals (1896212) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/26/2025 3:30 PM | Conduit Pharmaceuticals (1896212) Issuer Farley Chele Chiavacci (1908750) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/26/2025 3:30 PM | Conduit Pharmaceuticals (1896212) Issuer Lewis-Hall Freda C (1437909) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/26/2025 3:30 PM | Conduit Pharmaceuticals (1896212) Issuer Fry Simon Jeremy (2046305) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/18/2025 3:42 PM | Conduit Pharmaceuticals (1896212) Subject Sarborg Ltd (2066774) Filed by | Form SCHEDULE 13G/A | |
| 08/14/2025 12:11 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |